About: Carglumic Acid

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Carglumic Acid Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B53FB-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C: N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002 Dec;52(6):845-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12447942 # Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M: Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004 Oct;145(4):552-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15480384 # Summary of the European Public Assessment Report (EPAR) from European Medicines Agency. Last updated on 21/09/2009. "Carbaglu":http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000461/human_med_000685.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true # Thompson CA: Carglumic acid approved to treat genetic hyperammonemia. Am J Health Syst Pharm. 2010 May 1;67(9):690. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20410539 # Haberle J: Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:327-32. doi: 10.2147/TCRM.S12703. Epub 2011 Aug 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21941437 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Median values for the terminal half-life was 5.6 hours (range 4.3-9.5). (en)
http://linked.open...ugbank/indication	For the treatment of acute and chronic hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency. This enzyme is an important component of the urea cycle to prevent build up of neurotoxic ammonium in the blood. (en)
sameAs	Carglumic Acid
Title	Carglumic Acid (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/chemspider/108351 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/drugbank/DB06775 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/pubchem-compound/121396 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/pubchem-substance/99443290 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/chebi/71028 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/kegg-compound/C05829 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/kegg-drug/D07130 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/national-drug-code-directory/52276-312-05 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/pharmgkb/PA165958402 http://linked.opendata.cz/resource/drugbank/drug/DB06775/identifier/wikipedia/Carglumic_acid
http://linked.open...mechanismOfAction	Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG), which is an essential allosteric activator of the liver enzyme carbamoyl phosphate synthetase 1 (CPS1). CPS1 is found in the mitochondria and is the first enzyme of the urea cycle, which converts ammonia into urea. Carglumic acid acts as a replacement for NAG in NAGS deficiency patients by activating CPS1 but it does not help to regulate the urea cycle. (en)
http://linked.open...outeOfElimination	Following administration of a single radiolabeled oral dose of 100 mg/kg of body weight, 9% of the dose was excreted unchanged in the urine and up to 60% of the dose was excreted unchanged in the feces. (en)
http://linked.open.../drugbank/synonym	Carbaglu (en) (S)-2-ureidopentanedioic acid (en) N-Carbamyl-L-glutamate (en) (2S)-2-(Carbamoylamino)pentanedioic acid (en) Acide carglumique (en) Acido carglumico (en) Acidum carglumicum (en) Carbamino-L-glutamic acid (en) Carbamylglutamic acid (en) L-N-Carbamoylglutamic acid (en) N-Carbamoyl-L-Glutamic Acid (en) N-Carbamylglutamate (en) Ureidoglutaric acid (en)
http://linked.open...drugbank/toxicity	LD50, oral, mouse: >1000 mg/kg (en)
http://linked.open...umeOfDistribution	The apparent volume of distribution was 2657 L (range: 1616-5797). (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/40-10
foaf:page	http://www.drugs.com/carbaglu.html http://www.rxlist.com/carbaglu-drug.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5400-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5406-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5405-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5402-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5403-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5404-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B53FE-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B53FC-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B53FF-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5416-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B53FD-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Carglumic acid
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B540C-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B540D-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5407-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5408-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B540A-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5409-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B540B-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	30% bioavailability; Cmax, mean, 100 mg/kg dose = 2.6 μg/mL (range of 1.9 - 4.8) Carglumic acid is not subject to to intracellular degradation. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	1188-38-1 (en)
http://linked.open...rugbank/clearance	The apparent total clearance was 5.7 L/min (range 3.0-9.7), the renal clearance was 290 mL/min (range 204-445), and the 24-hour urinary excretion was 4.5 % of the dose (range 3.5-7.5). (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5412-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5414-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5415-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5411-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5410-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5413-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5401-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B540E-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B540F-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software